Insider Trading activities of Map Pharmaceuticals, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Map Pharmaceuticals, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Map Pharmaceuticals, Inc. since year 2005. Table 2 shows the detailed insider transactions of Map Pharmaceuticals, Inc. since 2005. The reporting company's ticker symbol is MAPP. The reporting company's CIK number is 1401923.
The total value of stock buying since 2005 is $22,658,629.
The total value of stock sales since 2005 is $52,538,154.
The total value of stock option exercises since 2005 is $1,966,281.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Map Pharmaceuticals, Inc. (MAPP).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2013-02 0 $0 31,429 $785,339 30,000 $326,799
2013-01 0 $0 170,384 $4,218,700 188,895 $615,471
2012-11 0 $0 11,007 $168,801 11,007 $47,121
2012-06 0 $0 0 $0 1,125 $0
2012-04 0 $0 2,500 $35,947 2,500 $15,975
2012-03 0 $0 20,000 $350,000 20,000 $187,620
2012-02 0 $0 92,500 $1,438,178 12,500 $79,875
2012-01 0 $0 4,471 $62,079 17,621 $3,321
2011-12 0 $0 41,341 $6,393,708 30,000 $20,249
2011-09 0 $0 32,000 $492,288 32,000 $23,776
2011-08 0 $0 0 $0 26,250 $0
2011-07 0 $0 1,500 $23,938 1,500 $1,114
2011-06 0 $0 1,500 $25,453 1,500 $1,114
2011-05 0 $0 6,500 $108,179 6,500 $4,829
2011-04 0 $0 1,500 $21,063 1,500 $1,114
2011-03 2,000 $31,380 31,500 $506,755 37,346 $27,747
2011-02 0 $0 2,500 $38,677 2,500 $1,857
2011-01 0 $0 2,500 $41,972 2,500 $1,857
2010-12 0 $0 5,620 $85,412 5,620 $34,211
2010-10 0 $0 17,564 $273,979 17,564 $95,746
2010-09 0 $0 19,250 $261,248 19,250 $14,302
2010-08 0 $0 15,250 $197,250 15,250 $11,330
2010-07 0 $0 34,250 $426,213 34,250 $23,917
2010-06 0 $0 33,250 $479,073 33,250 $21,643
2010-05 0 $0 50,810 $835,259 50,810 $49,709
2010-04 0 $0 14,965 $259,838 14,965 $123,898
2010-03 0 $0 1,430,927 $21,982,668 49,250 $33,532
2010-02 0 $0 8,250 $123,362 8,250 $6,129
2010-01 0 $0 29,500 $362,776 29,500 $19,878
2009-12 0 $0 14,500 $136,342 14,500 $36,973
2009-11 0 $0 30,750 $259,436 30,750 $21,189
2009-10 0 $0 14,500 $148,502 14,500 $10,773
2009-09 0 $0 4,500 $45,126 4,500 $3,343
2009-08 206,185 $1,999,994 0 $0 0 $0
2009-07 0 $0 82,100 $931,483 25,000 $18,575
2009-06 495 $5,603 342,039 $3,823,735 0 $0
2009-05 0 $0 522,837 $6,534,076 60,000 $44,580
2009-03 10,000 $21,660 0 $0 0 $0
2009-02 0 $0 15,021 $180,693 15,021 $11,160
2008-07 0 $0 11,900 $121,331 11,900 $8,838
2008-06 0 $0 7,500 $94,532 7,500 $5,572
2008-05 0 $0 22,400 $264,743 15,000 $11,144
2007-10 1,716,666 $20,599,992 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Map Pharmaceuticals, Inc. insiders (MAPP)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2013-02-28 Gianakakos Anastasios (SVP, Chief Business Officer) Sale 20,000 25.00 500,000
2013-02-28 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 20,000 10.37 207,399
2013-02-28 Henwood Geraldine (Director) Sale 10,000 25.00 250,000
2013-02-28 Henwood Geraldine (Director) Option Ex 10,000 11.94 119,400
2013-02-01 Kellerman Donald J (SVP,Clinical Dev & Med Affairs) Sale 1,429 24.73 35,339
2013-01-26 Borland Scott (SVP, Neurology Franchise) Sale 764 24.75 18,909
2013-01-26 Borland Scott (SVP, Neurology Franchise) Option Ex 1,900 .00 0
2013-01-26 Armer Thomas A (Chief Scientific Officer) Option Ex 2,250 .00 0
2013-01-26 Chai Christopher Y (SVP, Chief Financial Officer) Option Ex 2,250 .00 0
2013-01-26 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 2,250 .00 0
2013-01-26 Friedman Charlene A (SVP, Gen Counsel & Sec) Option Ex 2,250 .00 0
2013-01-26 Kellerman Donald J (SVP,Clinical Dev & Med Affairs) Option Ex 2,250 .00 0
2013-01-25 Borland Scott (SVP, Neurology Franchise) Option Ex 3,000 .00 0
2013-01-25 Armer Thomas A (Chief Scientific Officer) Option Ex 2,750 .00 0
2013-01-25 Chai Christopher Y (SVP, Chief Financial Officer) Option Ex 2,750 .00 0
2013-01-25 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 2,750 .00 0
2013-01-25 Friedman Charlene A (SVP, Gen Counsel & Sec) Option Ex 2,750 .00 0
2013-01-25 Nelson Timothy S (President and CEO) Option Ex 9,375 .00 0
2013-01-25 Kellerman Donald J (SVP,Clinical Dev & Med Affairs) Option Ex 2,750 .00 0
2013-01-23 Armer Thomas A (Chief Scientific Officer) Sale 59,620 24.76 1,476,191
2013-01-23 Armer Thomas A (Chief Scientific Officer) Option Ex 39,620 6.39 253,171
2013-01-23 Gianakakos Anastasios (SVP, Chief Business Officer) Sale 30,000 24.76 742,800
2013-01-23 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 30,000 10.37 311,100
2013-01-23 Nelson Timothy S (President and CEO) Sale 80,000 24.76 1,980,800
2013-01-23 Nelson Timothy S (President and CEO) Option Ex 80,000 .64 51,200
2012-11-23 Henwood Geraldine (Director) Sale 5,240 15.00 78,600
2012-11-23 Henwood Geraldine (Director) Option Ex 5,240 1.96 10,270
2012-11-01 Gianakakos Anastasios (SVP, Chief Business Officer) Sale 5,767 15.64 90,201
2012-11-01 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 5,767 6.39 36,851
2012-06-07 Borland Scott (SVP, Neurology Franchise) Option Ex 1,125 .00 0
2012-04-02 Gianakakos Anastasios (SVP, Chief Business Officer) Sale 2,500 14.38 35,947
2012-04-02 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 2,500 6.39 15,975
2012-03-09 Gianakakos Anastasios (SVP, Chief Business Officer) Sale 10,000 17.50 175,000
2012-03-09 Gianakakos Anastasios (SVP, Chief Business Officer) Option Ex 10,000 6.39 63,900
2012-03-09 Friedman Charlene A (SVP, Gen Counsel & Sec) Sale 10,000 17.50 175,000
2012-03-09 Friedman Charlene A (SVP, Gen Counsel & Sec) Option Ex 10,000 12.37 123,720
2012-02-21 Gianakakos Anastasios (SVP & Chief Business Officer) Sale 2,500 16.01 40,020
2012-02-21 Gianakakos Anastasios (SVP & Chief Business Officer) Option Ex 2,500 6.39 15,975
2012-02-14 Armer Thomas A (Chief Scientific Officer) Sale 30,999 15.62 484,142
2012-02-13 Armer Thomas A (Chief Scientific Officer) Sale 2,800 16.00 44,800
2012-02-08 Armer Thomas A (Chief Scientific Officer) Sale 26,201 16.00 419,216
2012-02-06 Armer Thomas A (Chief Scientific Officer) Sale 19,868 15.00 298,020
2012-02-06 Gianakakos Anastasios (SVP & Chief Business Officer) Sale 10,000 15.00 150,000
2012-02-06 Gianakakos Anastasios (SVP & Chief Business Officer) Option Ex 10,000 6.39 63,900
2012-02-03 Armer Thomas A (Chief Scientific Officer) Sale 132 15.00 1,980
2012-01-26 Borland Scott (SVP, Neurology Franchise) Option Ex 1,900 .00 0
2012-01-26 Armer Thomas A (Chief Scientific Officer) Option Ex 2,250 .00 0
2012-01-26 Chai Christopher Y (SVP & CFO) Option Ex 2,250 .00 0
2012-01-26 Gianakakos Anastasios (SVP & Chief Business Officer) Option Ex 2,250 .00 0
2012-01-26 Friedman Charlene A (SVP President, Gen Counsel&Sec) Option Ex 2,250 .00 0
2012-01-26 Kellerman Donald J (SVP,Clinical Dev & Med Affairs) Option Ex 2,250 .00 0
2012-01-19 Gianakakos Anastasios (SVP & Chief Business Officer) Sale 4,471 13.88 62,079
2012-01-19 Gianakakos Anastasios (SVP & Chief Business Officer) Option Ex 4,471 .74 3,321
2011-12-21 Nelson Timothy S (President and CEO) Sale 6,638 14.52 96,416
2011-12-21 Nelson Timothy S (President and CEO) Option Ex 6,638 .64 4,254
2011-12-20 Nelson Timothy S (President and CEO) Sale 13,362 14.50 193,815
2011-12-20 Nelson Timothy S (President and CEO) Option Ex 13,362 .64 8,565
2011-12-19 Armer Thomas A (See Remarks) Sale 20,000 14.00 280,000
2011-12-12 Gianakakos Anastasios (SVP & Chief Bus Officer) Sale 1,341 4,342.64 5,823,477
2011-12-12 Gianakakos Anastasios (SVP & Chief Bus Officer) Option Ex 10,000 .74 7,430
2011-09-20 Chai Christopher Y (Chief Financial Officer) Sale 32,000 15.38 492,288
2011-09-20 Chai Christopher Y (Chief Financial Officer) Option Ex 32,000 .74 23,776
2011-08-04 Borland Scott (SVP, Neurology Franchise) Option Ex 5,000 .00 0
2011-08-04 Nelson Timothy S (President and CEO) Option Ex 10,000 .00 0
2011-08-04 Kellerman Donald J (SVP,Clinical Dev & Med Affairs) Option Ex 11,250 .00 0
2011-07-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 1,500 15.96 23,938
2011-07-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 1,500 .74 1,114
2011-06-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 1,500 16.97 25,453
2011-06-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 1,500 .74 1,114
2011-05-09 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 5,000 17.00 85,000
2011-05-09 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 5,000 .74 3,715
2011-05-02 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 1,500 15.45 23,179
2011-05-02 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 1,500 .74 1,114
2011-04-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 1,500 14.04 21,063
2011-04-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 1,500 .74 1,114
2011-03-17 Armer Thomas A (Chief Scientific Officer) Option Ex 35,846 .74 26,633
2011-03-11 Ward Scott R (Director) Buy 2,000 15.69 31,380
2011-03-04 Armer Thomas A (Chief Scientific Officer) Sale 30,000 16.10 482,970
2011-03-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 1,500 15.86 23,785
2011-03-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 1,500 .74 1,114
2011-02-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 2,500 15.47 38,677
2011-02-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 2,500 .74 1,857
2011-01-03 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 2,500 16.79 41,972
2011-01-03 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 2,500 .74 1,857
2010-12-20 Friedman Charlene A (VP President, Gen Counsel &Sec) Sale 3,120 15.50 48,360
2010-12-20 Friedman Charlene A (VP President, Gen Counsel &Sec) Option Ex 3,120 10.37 32,354
2010-12-15 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 2,500 14.82 37,052
2010-12-15 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 2,500 .74 1,857
2010-10-27 Friedman Charlene A (VP President, Gen Counsel &Sec) Sale 7,800 15.52 121,095
2010-10-27 Friedman Charlene A (VP President, Gen Counsel &Sec) Option Ex 7,800 10.37 80,886
2010-10-27 Henwood Geraldine (Director) Sale 9,764 15.66 152,884
2010-10-27 Henwood Geraldine (Director) Option Ex 9,764 1.52 14,860
2010-09-20 Chai Christopher Y (Chief Financial Officer) Sale 16,000 14.05 224,816
2010-09-20 Chai Christopher Y (Chief Financial Officer) Option Ex 16,000 .74 11,888
2010-09-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 11.21 36,432
2010-09-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-08-05 Henwood Geraldine (Director) Sale 12,000 12.78 153,408
2010-08-05 Henwood Geraldine (Director) Option Ex 12,000 .74 8,916
2010-08-02 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 13.49 43,842
2010-08-02 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-07-21 Chai Christopher Y (Chief Financial Officer) Sale 8,000 13.00 104,000
2010-07-21 Chai Christopher Y (Chief Financial Officer) Option Ex 8,000 .74 5,944
2010-07-20 Chai Christopher Y (Chief Financial Officer) Sale 8,000 12.42 99,384
2010-07-20 Chai Christopher Y (Chief Financial Officer) Option Ex 8,000 .74 5,944
2010-07-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 12.47 40,534
2010-07-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-07-01 Nelson Timothy S (President and CEO) Sale 15,000 12.15 182,295
2010-07-01 Nelson Timothy S (President and CEO) Option Ex 15,000 .64 9,615
2010-06-03 Nelson Timothy S (President and CEO) Sale 3,480 14.16 49,294
2010-06-03 Nelson Timothy S (President and CEO) Option Ex 3,480 .64 2,230
2010-06-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 14.38 46,751
2010-06-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-06-01 Nelson Timothy S (President and CEO) Sale 26,520 14.44 383,028
2010-06-01 Nelson Timothy S (President and CEO) Option Ex 26,520 .64 16,999
2010-05-20 Chai Christopher Y (Chief Financial Officer) Sale 16,000 14.77 236,352
2010-05-20 Chai Christopher Y (Chief Financial Officer) Option Ex 16,000 .74 11,888
2010-05-13 Friedman Charlene A (VP President, Gen Counsel &Sec) Sale 1,560 17.07 26,633
2010-05-13 Friedman Charlene A (VP President, Gen Counsel &Sec) Option Ex 1,560 10.37 16,177
2010-05-13 Nelson Timothy S (President and CEO) Sale 30,000 17.09 512,790
2010-05-13 Nelson Timothy S (President and CEO) Option Ex 30,000 .64 19,230
2010-05-03 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 18.30 59,484
2010-05-03 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-04-26 Friedman Charlene A (VP President, Gen Counsel &Sec) Sale 10,155 18.03 183,064
2010-04-26 Friedman Charlene A (VP President, Gen Counsel &Sec) Option Ex 10,155 10.37 105,307
2010-04-14 Friedman Charlene A (VP President, Gen Counsel &Sec) Sale 1,560 16.05 25,041
2010-04-14 Friedman Charlene A (VP President, Gen Counsel &Sec) Option Ex 1,560 10.37 16,177
2010-04-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 15.92 51,733
2010-04-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-03-24 Chai Christopher Y (Chief Financial Officer) Sale 8,000 16.47 131,744
2010-03-24 Chai Christopher Y (Chief Financial Officer) Option Ex 8,000 .74 5,944
2010-03-23 Chai Christopher Y (Chief Financial Officer) Sale 8,000 16.72 133,792
2010-03-23 Chai Christopher Y (Chief Financial Officer) Option Ex 8,000 .74 5,944
2010-03-16 Goldfischer Carl (Director) Sale 115,610 16.20 1,872,882
2010-03-15 Goldfischer Carl (Director) Sale 42,176 16.01 675,237
2010-03-12 Soros Jonathan T Allan (10% Owner) Sale 706 16.11 11,373
2010-03-12 Goldfischer Carl (Director) Sale 105,000 16.30 1,711,500
2010-03-11 Bay City Capital Fund Iv, L.p. (10% Owner) Sale 54,300 16.06 872,057
2010-03-11 Goldfischer Carl (Director) Sale 54,300 16.06 872,057
2010-03-10 Bay City Capital Fund Iv, L.p. (10% Owner) Sale 134,190 16.03 2,151,065
2010-03-10 Elms Steve (Director) Sale 2,090 16.15 33,753
2010-03-10 Goldfischer Carl (Director) Sale 134,190 16.03 2,151,065
2010-03-10 Pearl Frank H (10% Owner) Sale 3,925 16.04 62,957
2010-03-09 Soros Jonathan T Allan (10% Owner) Sale 17,000 15.40 261,800
2010-03-09 Bay City Capital Fund Iv, L.p. (10% Owner) Sale 151,424 15.50 2,347,072
2010-03-09 Sfm Ah Llc (10% Owner) Sale 634 15.40 9,763
2010-03-09 Goldfischer Carl (Director) Sale 151,424 15.50 2,347,072
2010-03-09 Pearl Frank H (10% Owner) Sale 5,000 15.21 76,050
2010-03-08 Soros Jonathan T Allan (10% Owner) Sale 84,571 14.61 1,235,582
2010-03-08 Sfm Ah Llc (10% Owner) Sale 3,155 14.61 46,094
2010-03-08 Pearl Frank H (10% Owner) Sale 5,000 14.41 72,050
2010-03-05 Soros Jonathan T Allan (10% Owner) Sale 200,388 13.95 2,795,412
2010-03-05 Perseus Biotech Fund Partners Llc (10% Owner) Sale 25,488 13.95 355,557
2010-03-05 Perseus Soros Partners Llc (10% Owner) Sale 4,616 13.95 64,393
2010-03-05 Sfm Ah Llc (10% Owner) Sale 32,012 13.95 446,567
2010-03-05 Pearl Frank H (10% Owner) Sale 25,585 13.95 356,910
2010-03-04 Soros Jonathan T Allan (10% Owner) Sale 6,338 14.12 89,492
2010-03-04 Perseus Biotech Fund Partners Llc (10% Owner) Sale 3,738 14.15 52,892
2010-03-04 Perseus Soros Partners Llc (10% Owner) Sale 677 14.15 9,579
2010-03-04 Sfm Ah Llc (10% Owner) Sale 3,835 14.13 54,188
2010-03-04 Pearl Frank H (10% Owner) Sale 14,305 14.18 202,844
2010-03-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 3,250 14.08 45,769
2010-03-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 3,250 .74 2,414
2010-03-01 Nelson Timothy S (President and CEO) Sale 30,000 14.47 434,100
2010-03-01 Nelson Timothy S (President and CEO) Option Ex 30,000 .64 19,230
2010-02-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 8,250 14.95 123,362
2010-02-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 8,250 .74 6,129
2010-01-15 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 5,000 14.95 74,750
2010-01-15 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 5,000 .74 3,715
2010-01-11 Nelson Timothy S (President and CEO) Sale 20,000 12.17 243,400
2010-01-11 Nelson Timothy S (President and CEO) Option Ex 20,000 .64 12,820
2010-01-04 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 4,500 9.92 44,626
2010-01-04 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 4,500 .74 3,343
2009-12-14 Armer Thomas A (Chief Scientific Officer) Sale 10,000 9.54 95,370
2009-12-14 Armer Thomas A (Chief Scientific Officer) Option Ex 10,000 3.36 33,630
2009-12-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 4,500 9.10 40,972
2009-12-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 4,500 .74 3,343
2009-11-18 Henwood Geraldine (Director) Sale 16,250 8.77 142,447
2009-11-18 Henwood Geraldine (Director) Option Ex 16,250 .64 10,416
2009-11-02 Chai Christopher Y (Chief Financial Officer) Sale 10,000 8.07 80,719
2009-11-02 Chai Christopher Y (Chief Financial Officer) Option Ex 10,000 .74 7,430
2009-11-02 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 4,500 8.06 36,270
2009-11-02 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 4,500 .74 3,343
2009-10-01 Chai Christopher Y (Chief Financial Officer) Sale 10,000 10.26 102,620
2009-10-01 Chai Christopher Y (Chief Financial Officer) Option Ex 10,000 .74 7,430
2009-10-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 4,500 10.20 45,882
2009-10-01 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 4,500 .74 3,343
2009-09-08 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 4,500 10.03 45,126
2009-09-08 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 4,500 .74 3,343
2009-08-06 Freund John Gordon (Director) Buy 206,185 9.70 1,999,994
2009-07-15 Firstmark Capital, L.l.c. (Other) Sale 960 10.50 10,080
2009-07-14 Firstmark Capital, L.l.c. (Other) Sale 8,740 10.61 92,696
2009-07-10 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 25,000 10.16 254,000
2009-07-10 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 25,000 .74 18,575
2009-07-02 Firstmark Capital, L.l.c. (Other) Sale 2,400 12.00 28,812
2009-07-01 Firstmark Capital, L.l.c. (Other) Sale 45,000 12.13 545,895
2009-06-26 Firstmark Capital, L.l.c. (Other) Sale 132,100 11.25 1,481,226
2009-06-24 Firstmark Capital, L.l.c. (Other) Sale 2,900 11.02 31,958
2009-06-23 Firstmark Capital, L.l.c. (Other) Sale 76,084 11.26 847,499
2009-06-19 Firstmark Capital, L.l.c. (Other) Buy 495 11.32 5,603
2009-06-19 Firstmark Capital, L.l.c. (Other) Sale 38,421 11.35 430,883
2009-05-28 Firstmark Capital, L.l.c. (Other) Sale 250,000 13.38 3,292,148
2009-05-27 Firstmark Capital, L.l.c. (Other) Sale 5,000 12.00 60,010
2009-05-27 Armer Thomas A (Chief Scientific Officer) Sale 60,000 10.01 600,600
2009-05-27 Armer Thomas A (Chief Scientific Officer) Option Ex 60,000 .74 44,580
2009-05-26 Armer Thomas A (Chief Scientific Officer) Sale 40,000 9.00 360,000
2009-03-05 Nelson Timothy S (President and CEO, Director) Buy 10,000 2.17 21,660
2009-02-09 Chai Christopher Y (Chief Financial Officer) Sale 21 13.00 273
2009-02-09 Chai Christopher Y (Chief Financial Officer) Option Ex 21 .74 15
2009-02-04 Gianakakos Anastasios (SVP, Cor & Business Dev) Sale 15,000 12.03 180,420
2009-02-04 Gianakakos Anastasios (SVP, Cor & Business Dev) Option Ex 15,000 .74 11,145
2008-07-07 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 600 10.03 6,016
2008-07-07 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 600 .74 445
2008-07-03 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 800 10.20 8,156
2008-07-03 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 800 .74 594
2008-07-02 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 4,400 10.11 44,488
2008-07-02 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 4,400 .74 3,268
2008-07-01 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 3,900 10.37 40,427
2008-07-01 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 3,900 .74 2,897
2008-06-04 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 3,500 12.73 44,548
2008-06-04 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 3,500 .74 2,600
2008-06-02 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 4,000 12.50 49,984
2008-06-02 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 4,000 .74 2,972
2008-05-19 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 1,700 10.95 18,616
2008-05-19 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 1,700 .74 1,263
2008-05-16 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 5,300 11.61 61,511
2008-05-16 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 5,300 .74 3,937
2008-05-15 Gianakakos Anastasios (SVP, COR & Business Dev) Sale 8,000 12.04 95,935
2008-05-15 Gianakakos Anastasios (SVP, COR & Business Dev) Option Ex 8,000 .74 5,944
2007-10-11 Soros Jonathan T Allan (10% Owner) Buy 175,000 12.00 2,100,000
2007-10-11 Pearl Frank H (10% Owner) Buy 175,000 12.00 2,100,000
2007-10-05 Skyline Venture Partners Qualified Purchaser Fund (10% Owner) Buy 83,333 12.00 999,996
2007-10-05 Freund John Gordon (Director) Buy 83,333 12.00 999,996
2007-10-05 Mcpherron Matthew V (Director) Buy 600,000 12.00 7,200,000
2007-10-05 Brookside Capital Partners Fund Lp (10% Owner) Buy 600,000 12.00 7,200,000

Insider trading activities including stock purchases, stock sales, and option exercises of MAPP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Map Pharmaceuticals, Inc. (symbol MAPP, CIK number 1401923) see the Securities and Exchange Commission (SEC) website.